Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Ipilimumab × Tumor-Agnostic × Clear all

Phase

Status

Completed 13 Active not recruiting 5 Terminated 3 Withdrawn 1 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 15 Genitourinary 3 Thoracic 2 Sarcoma 2 Other hematologic neoplasm 2 Gynecologic 2 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Lymphoid 1 CNS 1 Breast 1

Conditions

Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 4 Cisplatin 4 Gemcitabine 3 trametinib 2 repotrectinib 2 pembrolizumab 2 enzalutamide 2 atezolizumab 2 Surveys and Questionnaires 2 SS1(dsFv)PE38 2 Radiotherapy 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 veliparib 1 vadimezan 1 toripalimab 1 talazoparib 1 sintilimab 1 reolysin 1 pertuzumab 1 peginterferon alfa-2a 1 palbociclib 1 onartuzumab 1 nintedanib 1 nimotuzumab 1 naquotinib 1 montanide ISA 51 1 lenvatinib 1 folfirinox 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04315155 2020-10-28

BENEFIT

University of Utah

Phase 1 Withdrawn

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡